CD19 and polycystic ovary syndrome: In one study, infusion of CD19 antibodies into PCOS mice significantly reduced peripheral B lymphocyte counts, decreased cystic follicle numbers, and increased corpus luteum formation, suggesting that these immune cells, along with antibodies and cytokines, could serve as potential therapeutic targets for PCOS (7).